Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer

BACKGROUND: Durvalumab consolidation is associated with improved survival following concurrent chemoradiotherapy (CCRT) in patients with stage III non‐small cell lung cancer (NSCLC). Given the heterogeneity of stage III NSCLC patients, in this study we evaluated the efficacy and safety of durvalumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yiqing, Zhao, Joseph J., Soon, Yu Yang, Wong, Alvin, Aminkeng, Folefac, Ang, Yvonne, Asokumaran, Yugarajah, Low, Jia Li, Lee, Matilda, Choo, Joan R. E., Chan, Gloria, Kee, Adrian, Tay, Sen Hee, Goh, Boon Cher, Soo, Ross A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663681/
https://www.ncbi.nlm.nih.gov/pubmed/36177913
http://dx.doi.org/10.1111/1759-7714.14667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663681/
https://www.ncbi.nlm.nih.gov/pubmed/36177913
http://dx.doi.org/10.1111/1759-7714.14667

Ejemplares similares